The updated guidelines suggest more testing and get more into the genomic markers. For Glioblastoma, the big change is that Optune (listed as "Tumor Treating Fields (TTF)") is now included in the preferred regimen for patients with a karnofsky score of 60 or more. In the last version of the guidelines, it was just one of a few choices.